Combining stereotactic radiosurgery with an epidermal growth factor receptor-tyrosine kinase inhibitor may benefit patients with brain metastases from NSCLC but further study is needed to change standard of care.
Combination of EGRF and transforming growth factor beta shows promising results for treating metastatic head and neck squamous cell carcinoma.
Preliminary results from the phase 3 ADAURA trial indicate that osimertinib is superior to placebo in adjuvant treatment of EGFR-mutated non-small cell lung cancer.
Biologic therapies, such as epidermal growth factor receptor inhibitors, have revolutionized medicine and offer targeted therapy for an increasing number of diseases; however, along with these advances and their ensuing expanded use have come many unique adverse effects. In this article, dermatologists review how to manage cutaneous adverse effects of EFGR inhibitors and when to consult a dermatologist.